Download Free Guide To Monitoring And Evaluation For Collaborative Tb Hiv Activities 2015 Update Book in PDF and EPUB Free Download. You can read online Guide To Monitoring And Evaluation For Collaborative Tb Hiv Activities 2015 Update and write the review.

Preceded by A guide to monitoring and evaluation for collaborative TB/HIV activities. 2009 revision. 2009.
This manual is designed for health professionals working in high HIV and TB prevalence countries. It summarises the characteristics of both diseases and their interactions. It concentrates particularly on the problems of diagnosis and management both in adults and children and summarises the other HIV related illnesses the clinician might encounter.
Addressing comorbidities and risk factors for tuberculosis (TB) is a crucial component of the World Health Organization (WHO)’s End TB Strategy. These consolidated guidelines on tuberculosis. Module 6: tuberculosis and comorbidities summarize the latest WHO recommendations on TB and key comorbidities. It is a living document and will include a separate section for each of the key TB comorbidities or health-related risk factors. This first edition focuses on interventions to address HIV-associated TB and is an update of the WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. People with HIV are 12–16 times more likely to develop TB disease, have poorer TB treatment outcomes and have three-fold higher mortality during TB treatment compared to people without HIV. Despite advances in the screening, diagnosis, treatment and prevention of TB disease, TB remains the leading cause of death among people with HIV worldwide. These consolidated guidelines are intended for use by people working in ministries of health, particularly TB programmes and the relevant departments or programmes responsible for comorbidities and health-related risk factors for TB, as well as programmes addressing mental health and lung health, implementing partners including technical and funding agencies, civil society and representatives of affected communities, clinicians and public health practitioners.
With over 10 million new TB cases and 1.6 million deaths, TB is a global health priority. Multidrug-resistant TB is of particular concern to both clinicians and national TB programmes: in 2017, there were 558 000 new rifampicin-resistant cases and 460 000 confirmed multidrug-resistant TB cases. Despite extensive investigation over the years, there is still a great deal to learn about the prevention, diagnosis and treatment of TB. This Monograph brings together chapters from global TB experts and begins with a patients’ perspective that sets the tone. The following chapters cover: the history of TB; epidemiology; strategies for control and elimination; clinical and laboratory diagnosis; imaging; treatment and drugs; TB in children and different patient populations; comorbidities; clinical cases; and much more.
Access the latest information available in the challenging area of HIV/AIDS management with Sande's HIV/AIDS Medicine, 2nd Edition. Authored by a veritable "who's who" of current global experts in the field, this medical reference book will provide you with all the practical, indispensable guidance you'll need to offer your patients the best possible care. Access reliable, up-to-the-minute guidance that addresses the realities of HIV/AIDS management in your geographical region, thanks to contributions from a global cast of renowned expert clinicians and researchers. Locate the clinically actionable information you need quickly with an organization that mirrors the current state of the AIDS epidemic and the different needs of Western vs. developing-world patients and clinicians. Diagnose AIDS manifestations confidently by comparing them to clinical images. Improve patient outcomes with the latest findings on the management of AIDS as a chronic illness. Efficiently review essential data through numerous at-a-glance tables. Get the most relevant information available on pediatric HIV and AIDS issues; anti-retroviral drugs, including integrase inhibitors; and the use of second- and third-line anti-retroviral drugs in resource-poor settings. Stay current on the latest actionable information, such as using antiretroviral therapy in patients with tuberculosis and drug-resistant tuberculosis; antiretroviral therapy; immune reconstitution inflammatory syndromes (IRIS); and implementation of the HPV vaccine.